Vitreoretinal lymphoma occurring after systemic chemotherapy for primary conjunctival diffuse large B cell lymphoma: A case report.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
received:
28
06
2021
accepted:
09
09
2021
entrez:
1
10
2021
pubmed:
2
10
2021
medline:
13
10
2021
Statut:
ppublish
Résumé
Ocular adnexal lymphoma and vitreoretinal lymphoma are rare forms of non-Hodgkin lymphoma. They are regarded as distinct disease entities due to the differences in molecular mechanism, management, and outcome. We present a rare case of conjunctival diffuse large B cell lymphoma (DLBCL) that developed to vitreoretinal lymphoma after systemic chemotherapy. A 60-year-old man presented with a left salmon-colored conjunctival mass. A biopsy was performed, and histopathologic examination showed DLBCL. Immunohistochemical staining was positive for CD20 with increased κ to λ light chain ratio. Bone marrow biopsy also revealed DLBCL. Gallium-67 scintigraphy showed abnormal uptake only in the left orbital lesion. Ann Arbor stage was estimated as IV. The patient underwent systemic combination chemotherapy and immunotherapy. Four months after the last course of chemotherapy, primary conjunctival DLBCL relapsed, manifesting vitreous opacity. Diagnostic vitrectomy confirmed a diagnosis of vitreoretinal lymphoma. Conjunctival DLBCL and vitreoretinal lymphoma are both DLBCL. After systemic chemotherapy for conjunctival DLBCL, the lymphoma may relapse in intraocular sites as secondary vitreoretinal lymphoma.
Identifiants
pubmed: 34596140
doi: 10.1097/MD.0000000000027347
pii: 00005792-202110010-00034
pmc: PMC8483852
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e27347Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
Ocul Immunol Inflamm. 2017 Oct;25(5):654-662
pubmed: 27070953
Ophthalmology. 2008 Sep;115(9):1626-31, 1631.e1-3
pubmed: 18440641
Eye (Lond). 2003 May;17(4):513-21
pubmed: 12802353
Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3283-8
pubmed: 18390644
JAMA Ophthalmol. 2013 Sep;131(9):1151-8
pubmed: 23744124
Clin Exp Med. 2018 May;18(2):151-163
pubmed: 28939925
Surv Ophthalmol. 2006 Jan-Feb;51(1):41-50
pubmed: 16414360
Jpn J Ophthalmol. 2012 Jul;56(4):383-9
pubmed: 22661396
Br J Ophthalmol. 1988 Dec;72(12):905-11
pubmed: 3067746
Am J Ophthalmol. 1997 Sep;124(3):362-72
pubmed: 9439362
Br J Ophthalmol. 2008 Feb;92(2):296-7
pubmed: 18227215
Clin Ophthalmol. 2019 Feb 14;13:353-364
pubmed: 30858685
Ocul Immunol Inflamm. 2009 Mar-Apr;17(2):69-72
pubmed: 19412864
Eye Vis (Lond). 2019 Jul 27;6:22
pubmed: 31372366
Ocul Immunol Inflamm. 2021 Apr 3;29(3):479-484
pubmed: 32967510
J Ophthalmic Inflamm Infect. 2019 Jun 10;9(1):11
pubmed: 31183567
JAMA Ophthalmol. 2013 Jan;131(1):50-5
pubmed: 23307208
Am J Ophthalmol Case Rep. 2019 Aug 15;16:100545
pubmed: 31468000
Ophthalmology. 2004 Jun;111(6):1233-7
pubmed: 15177977
Br J Haematol. 2018 Nov;183(4):668-671
pubmed: 29143310
Ophthalmology. 2018 Jan;125(1):127-136
pubmed: 28712656
Surv Ophthalmol. 2015 Sep-Oct;60(5):444-58
pubmed: 26003619
Orbit. 2002 Jun;21(2):117-23
pubmed: 12029566
Acta Ophthalmol. 2011 Mar;89(2):e149-54
pubmed: 19958292
Ophthalmology. 2001 May;108(5):979-84
pubmed: 11320031
J Ophthalmol. 2019 Oct 16;2019:6327041
pubmed: 31737358
J Clin Exp Hematop. 2018 Dec 13;58(4):180-183
pubmed: 30416173
JAMA Ophthalmol. 2016 Apr;134(4):406-14
pubmed: 26891973